Div Gupta

Cooley advised CinCor Pharma, a clinical-stage biopharmaceutical company, on its definitive agreement to be acquired by AstraZeneca. M&A partners Rama Padmanabhan and Rowook Park and corporate partners Div Gupta and Sarah Sellers led the Cooley team.

Cooley advised Oyster Point Pharma, a top ophthalmology-focused biopharmaceutical company, on its definitive agreement to be acquired by global healthcare company Viatris. Partners Mika Reiner Mayer, Brandon Fenn, Div Gupta and Ian Nussbaum led the Cooley team advising Oyster Point Pharma.

Cooley advised the underwriters in Karuna Therapeutics’ $862.5 million follow-on offering of 4,011,628 shares of common stock at a public offering price of $215 per share. Karuna is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. Partners Richard Segal, Jean Park, Div Gupta and associate Darah Protas led the Cooley team.

Cooley advised Silence Therapeutics in a $56.5 million registered direct offering of 5,950,000 American Depositary Shares (ADS), each representing three ordinary shares, at a price of $9.50 per ADS. Silence is a biotechnology company focused on discovering and developing molecules incorporating novel short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Partners Josh Kaufman, Div Gupta, Nicolas H.R. Dumont and Claire Keast-Butler led the Cooley team.

Cooley advised the underwriters in Cerevel Therapeutics’ $253.8 million follow-on offering of 7,250,000 shares of its common stock at a public offering price of $35 per share and the initial purchasers in its $345.0 million Rule 144A convertible notes offering. Cerevel is a clinical-stage biopharmaceutical company pursuing a targeted approach to neuroscience that combines a deep understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system target receptor selective pharmacology to discover and design new therapies. Lawyers Div Gupta, Daniel Goldberg, Eric Blanchard, Mischi a Marca, Jason Savich, Minkyu Park, Amiti Rothstein, Ellie Guadiana, Matt Kong, Eric Delgado and Jordan Verrilli led the Cooley team.